• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Sorrento Therapeutics Stock Is Not That Attractive Now

I like to look for more compelling setups.
By BRUCE KAMICH
Oct 16, 2020 | 09:01 AM EDT
Stocks quotes in this article: SRNE, REGN

In his first "Executive Decision" segment his Mad Money program Thursday night, Jim Cramer spoke with Dr. Henry Ji, chairman, president and CEO of Sorrento Therapeutics (SRNE) , the biotech company that is working towards treatments for Covid-19.

Ji said work continues on the company's neutralizing antibody therapy for Covid-19. Sorrento just entered clinical trials for its first-generation therapy and are on track to be filing to test their second generation in late November. He said it's been very encouraged by the success of Regeneron (REGN) , which has a similar therapy.  Work is continuing on Sorrento's rapid test for Covid as well.  

We last looked at SRNE on Aug. 11 and wrote that, "A possible harami reversal on the candlestick chart and the first sign that trading volume could be increasing on a down day (a peak in the OBV line) suggest that short-term traders may want to nail down profits and trade more cautiously." Prices quickly retreated to $6 so our advice looks well timed. 

 
Let's check out SRNE charts again today.
 
In the updated daily bar chart of SRNE, below, we can see that the shares rebounded after their August-September decline. The recovery is not quite 50% of the decline so SRNE did not put the bears on the defensive. In my mind a recovery of more than 50% of decline makes the bears or shorts sweat. Less than 50% tells me they are still in control.
 
The On-Balance-Volume (OBV) line made a shallow decline from August into September and a shallow recovery from September. Buyers are only slightly more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is above the zero line again but looks like it is rolling over toward a new sell signal. 
 
 
 
In the weekly bar chart of SRNE, below, we see a mixed picture. The shares are above the rising 40-week moving average line but the indicators do not tell us a bullish story. We can see volume surges at the two price spikes this year suggesting that there might be longs stuck at unfavorable price levels. This overhang or resistance may be an impediment to renewed gains.
 
The OBV line shows an up and down pattern and no sustained buying. The MACD oscillator is pointed down. 
 
 
In this daily Point and Figure chart of SRNE, below, we can see a potential downside price target in the $8.50 area. If this decline were to occur it would put prices below the cresting 50-day moving average line.  
 
 
Bottom-line strategy: The charts and indicators of SRNE are not particularly bullish. I like to look for more compelling setups. I would stand aside for now.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Mad Money | Executive Interview | Coronavirus

More from Stocks

What Really Happened Wednesday, Is This 'It'?, Fed, Trading Apple, Tesla, AMD

Stephen Guilfoyle
Jan 28, 2021 7:40 AM EST

Everyone gets frightened. Everyone fears the water moccasin when hip deep in the swamp. Everyone fears what they cannot see, and what they do not understand.

A Recipe for a Rebound

Paul Price
Jan 28, 2021 7:00 AM EST

Here's how to play Ingredion as it looks set to rise.

A Rush to Rotate Into Short-Squeeze Plays Is Roiling the Market

James "Rev Shark" DePorre
Jan 28, 2021 6:27 AM EST

The market is struggling with instability as a massive, short-squeeze movement continues. 'Good' stocks are being dumped by funds to pay for short-selling losses.

If You Think the Selling Started Yesterday, You Have a Short Memory

Helene Meisler
Jan 28, 2021 6:00 AM EST

A lot of what we saw on Wednesday has been in the works for a while now.

Emotions Run High as Indexes Slip

James "Rev Shark" DePorre
Jan 27, 2021 4:44 PM EST

I've raised a bit of cash, but it's still unclear what will emerge from here.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 06:43 AM EST BOB LANG

    Webinar Time -- After the Close today

    join me later today as we talk about markets and w...
  • 11:48 AM EST STEPHEN GUILFOYLE

    Cashing in Some More Chips at Stocks Under $10

    We're trimming a position for a big gain today.
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/27/2021

    The "correction" can be coming sooner than we thou...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login